Jyotirmay Biswas1, Reesha K R2, Bikramjit Pal3, Harshal P Gondhale4, Ranju Kharel Sitaula4,5. 1. a Medical and Vision Research Foundations, Sankara Nethralaya, Uvea and Ocular Pathology , Chennai , Tamil Nadu , India. 2. b Little Flower Hospital , Angamaly Ernakulam Kerala , India. 3. c Shri Bhagwan Mahavir Vitreoretinal Services , Sankara Nethralaya, Medical Research Foundation , Chennai , Tamil Nadu , India. 4. d Sankara Nethralaya , Medical Research Foundation , Chennai , Tamil Nadu , India. 5. e Department of Ophthalmology, Maharajgunj Medical Campus , B.P.Koirala Lions Centre for Ophthalmic Studies, Institute of Medicine , Teaching University , Kathmandu , Nepal.
Abstract
PURPOSE: To analyze the long-term visual outcomes of Eales' patients. METHODS: A retrospective review of Eales' patients diagnosed between 1985 and 1995 with >10 years follow-up done. RESULTS: We included 500 patients (898 eyes) with mean follow-up duration of 15.8 years (10-25 years), and 81% patients had bilateral disease. Patients using oral steroid during acute stage disease had significantly better visual outcome at the final visit [0.42 logMar(6/18) ± 0.723 logMar(6/30)] compared to patients who did not receive oral steroids [(0.5907 logMar(6/24) ± 0.945 logMar(6/48)] (p = 0.004). Patients who received laser therapy had significantly better visual outcome at the final visit [(0.415 logMar(6/18) ± 0.66 logMar(6/30)] compared to those who did not undergo laser treatment [(0.9237 logMar(6/48) ± 1.31 logMar(6/120)] (p < 0.001). Poor presenting visual acuity and late stage of presentation were associated with poor visual outcome. Fifty-two percent of eyes had <5 recurrences over 10 years. CONCLUSION: Eales' disease is a bilateral recurrent retinal vasculitis disorder and timely treatment with steroid and/or laser photocoagulation result in better visual outcomes.
PURPOSE: To analyze the long-term visual outcomes of Eales' patients. METHODS: A retrospective review of Eales' patients diagnosed between 1985 and 1995 with >10 years follow-up done. RESULTS: We included 500 patients (898 eyes) with mean follow-up duration of 15.8 years (10-25 years), and 81% patients had bilateral disease. Patients using oral steroid during acute stage disease had significantly better visual outcome at the final visit [0.42 logMar(6/18) ± 0.723 logMar(6/30)] compared to patients who did not receive oral steroids [(0.5907 logMar(6/24) ± 0.945 logMar(6/48)] (p = 0.004). Patients who received laser therapy had significantly better visual outcome at the final visit [(0.415 logMar(6/18) ± 0.66 logMar(6/30)] compared to those who did not undergo laser treatment [(0.9237 logMar(6/48) ± 1.31 logMar(6/120)] (p < 0.001). Poor presenting visual acuity and late stage of presentation were associated with poor visual outcome. Fifty-two percent of eyes had <5 recurrences over 10 years. CONCLUSION: Eales' disease is a bilateral recurrent retinal vasculitis disorder and timely treatment with steroid and/or laser photocoagulation result in better visual outcomes.
Authors: Noemi Guemes-Villahoz; Barbara Burgos-Blasco; Beatriz Vidal-Villegas; Juan Donate-López; Francisco Javier Martín-Sánchez; Jesús Porta-Etessam; Lorenzo López-Guajardo; José Luis R Martín; Juan Jorge González-Armengol; Julián García-Feijoó Journal: Med Clin (Engl Ed) Date: 2021-06-05